Not known Facts About Imipenem
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review To judge a number of intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Main trial targets had been To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis pat